封面
市场调查报告书
商品编码
1878846

奈米医学市场-全球产业规模、份额、趋势、机会和预测,按奈米分子类型、奈米颗粒类型、应用、疾病适应症、地区和竞争格局划分,2020-2030年预测

Nanomedicine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Nanomolecule Type, By Nanoparticles Type, By Application By Disease Indication, By Region and Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024年全球奈米医学市场规模为1,741亿美元,预计2030年将以9.10%的复合年增长率成长至2,935.9亿美元。奈米医学是指将奈米技术应用于医疗保健领域,利用尺寸通常在1至100奈米之间的材料和设备进行疾病的诊断、治疗和预防。这种方法利用奈米结构的独特特性来提高药物的溶解度、稳定性、标靶递送和生物利用度。

市场概览
预测期 2026-2030
2024年市场规模 1741亿美元
2030年市场规模 2935.9亿美元
2025-2030年复合年增长率 9.1%
成长最快的细分市场 奈米颗粒
最大的市场 北美洲

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章:产品概述

第二章:研究方法

第三章:执行概要

第四章:客户之声

第五章:全球奈米医学市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依奈米分子类型(奈米颗粒、奈米壳、奈米装置、奈米管)
    • 依奈米颗粒类型(聚合物基、脂质基、奈米晶体、无机、其他)
    • 依应用领域(药物传递、疫苗、诊断影像、再生医学、其他)
    • 依疾病适应症分类(肿瘤疾病、传染病、骨科疾病、心血管疾病、其他)
    • 按地区
    • 按公司(2024 年)
  • 市场地图

第六章:北美奈米医学市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲:国家分析
    • 美国
    • 加拿大
    • 墨西哥

第七章:欧洲奈米医学市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲:国家分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章:亚太纳米医药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区:国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章:中东与非洲奈米医学市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东和非洲:国家分析
    • 沙乌地阿拉伯
    • 阿联酋
    • 南非

第十章:南美洲纳米医药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲:国家分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章:市场动态

  • 司机
  • 挑战

第十二章:市场趋势与发展

  • 併购(如有)
  • 产品发布(如有)
  • 最新进展

第十三章:全球奈米医学市场:SWOT分析

第十四章:波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商议价能力
  • 顾客的力量
  • 替代产品的威胁

第十五章:竞争格局

  • Pfizer Inc.
  • Johnson & Johnson Innovative Medicine
  • Sanofi SA
  • Amgen Inc.
  • Moderna, Inc.
  • Novo Nordisk A/S
  • Genentech, Inc.
  • Celgene Corporation
  • Vifor Pharma Group
  • Teva Pharmaceutical Industries Ltd.

第十六章:策略建议

第17章调查会社について・免责事项

简介目录
Product Code: 10570

The Global Nanomedicine Market, valued at USD 174.10 Billion in 2024, is projected to experience a CAGR of 9.10% to reach USD 293.59 Billion by 2030. Nanomedicine represents the application of nanotechnology in healthcare, utilizing materials and devices typically ranging from 1 to 100 nanometers for the diagnosis, treatment, and prevention of diseases. This approach leverages the unique properties of nanoscale structures to enhance drug solubility, stability, targeted delivery, and bioavailability.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 174.10 Billion
Market Size 2030USD 293.59 Billion
CAGR 2025-20309.1%
Fastest Growing SegmentNanoparticles
Largest MarketNorth America

Key Market Drivers

The global nanomedicine market experiences significant impetus from two primary factors: ongoing advancements in nanotechnology innovation and the increasing prevalence of chronic diseases. Technological progress consistently yields novel tools and materials, enabling sophisticated diagnostic and therapeutic applications within healthcare. For instance, according to the National Institutes of Health, in July 2023, the Notice of Funding Opportunity for "Innovative Research in Cancer Nanotechnology (IRCN) R01 Grant" was published, with application deadlines including November 2023 and May 2024, demonstrating sustained investment in fundamental research in this specialized area. Concurrently, the rising global burden of chronic diseases intensifies the demand for more effective medical interventions.

Key Market Challenges

A significant challenge impeding the expansion of the Global Nanomedicine Market is the substantial cost associated with the development and complex manufacturing processes of these specialized products. The intricate nature of nanotechnology-based interventions necessitates considerable upfront investment in research, highly specialized equipment, advanced infrastructure, and a workforce with unique expertise. These requirements often lead to protracted development timelines and increased operational expenditures throughout the product lifecycle, from initial synthesis to large-scale production.

Key Market Trends

The increasing shift towards personalized nanomedicine stands as a significant factor shaping the global nanomedicine market. This trend emphasizes tailoring medical treatments to individual patient characteristics, leveraging nanotechnology's ability to deliver drugs precisely and enhance diagnostic accuracy. Personalized nanomedicine offers the potential for improved therapeutic efficacy and reduced adverse effects by targeting specific cells or tissues. According to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U. S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a notable increase from the 12 approved in 2022. This demonstrates a growing regulatory recognition and market adoption of personalized approaches, which nanomedicine profoundly supports.

Key Market Players

  • Pfizer Inc.
  • Johnson & Johnson Innovative Medicine
  • Sanofi S.A.
  • Amgen Inc.
  • Moderna, Inc.
  • Novo Nordisk A/S
  • Genentech, Inc.
  • Celgene Corporation
  • Vifor Pharma Group
  • Teva Pharmaceutical Industries Ltd.

Report Scope:

In this report, the Global Nanomedicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Nanomedicine Market, By Nanomolecule Type:

  • Nanoparticles
  • Nanoshells
  • Nanodevices
  • Nanotubes

Nanomedicine Market, By Nanoparticles Type:

  • Polymer-based
  • Lipid-based
  • Nanocrystals
  • Inorganic
  • Others

Nanomedicine Market, By Application:

  • Drug Delivery
  • Vaccines
  • Diagnostic Imaging
  • Regenerative Medicine
  • Others

Nanomedicine Market, By Disease Indication:

  • Oncological Diseases
  • Infectious Diseases
  • Orthopedic Disorders
  • Cardiovascular Diseases
  • Others

Nanomedicine Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Nanomedicine Market.

Available Customizations:

Global Nanomedicine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Nanomedicine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Nanomolecule Type (Nanoparticles, Nanoshells, Nanodevices, Nanotubes)
    • 5.2.2. By Nanoparticles Type (Polymer-based, Lipid-based, Nanocrystals, Inorganic, Others)
    • 5.2.3. By Application (Drug Delivery, Vaccines, Diagnostic Imaging, Regenerative Medicine, Others)
    • 5.2.4. By Disease Indication (Oncological Diseases, Infectious Diseases, Orthopedic Disorders, Cardiovascular Diseases, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2024)
  • 5.3. Market Map

6. North America Nanomedicine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Nanomolecule Type
    • 6.2.2. By Nanoparticles Type
    • 6.2.3. By Application
    • 6.2.4. By Disease Indication
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Nanomedicine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Nanomolecule Type
        • 6.3.1.2.2. By Nanoparticles Type
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By Disease Indication
    • 6.3.2. Canada Nanomedicine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Nanomolecule Type
        • 6.3.2.2.2. By Nanoparticles Type
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By Disease Indication
    • 6.3.3. Mexico Nanomedicine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Nanomolecule Type
        • 6.3.3.2.2. By Nanoparticles Type
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By Disease Indication

7. Europe Nanomedicine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Nanomolecule Type
    • 7.2.2. By Nanoparticles Type
    • 7.2.3. By Application
    • 7.2.4. By Disease Indication
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Nanomedicine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Nanomolecule Type
        • 7.3.1.2.2. By Nanoparticles Type
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By Disease Indication
    • 7.3.2. France Nanomedicine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Nanomolecule Type
        • 7.3.2.2.2. By Nanoparticles Type
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By Disease Indication
    • 7.3.3. United Kingdom Nanomedicine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Nanomolecule Type
        • 7.3.3.2.2. By Nanoparticles Type
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By Disease Indication
    • 7.3.4. Italy Nanomedicine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Nanomolecule Type
        • 7.3.4.2.2. By Nanoparticles Type
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By Disease Indication
    • 7.3.5. Spain Nanomedicine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Nanomolecule Type
        • 7.3.5.2.2. By Nanoparticles Type
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By Disease Indication

8. Asia Pacific Nanomedicine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Nanomolecule Type
    • 8.2.2. By Nanoparticles Type
    • 8.2.3. By Application
    • 8.2.4. By Disease Indication
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Nanomedicine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Nanomolecule Type
        • 8.3.1.2.2. By Nanoparticles Type
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By Disease Indication
    • 8.3.2. India Nanomedicine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Nanomolecule Type
        • 8.3.2.2.2. By Nanoparticles Type
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By Disease Indication
    • 8.3.3. Japan Nanomedicine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Nanomolecule Type
        • 8.3.3.2.2. By Nanoparticles Type
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By Disease Indication
    • 8.3.4. South Korea Nanomedicine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Nanomolecule Type
        • 8.3.4.2.2. By Nanoparticles Type
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By Disease Indication
    • 8.3.5. Australia Nanomedicine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Nanomolecule Type
        • 8.3.5.2.2. By Nanoparticles Type
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By Disease Indication

9. Middle East & Africa Nanomedicine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Nanomolecule Type
    • 9.2.2. By Nanoparticles Type
    • 9.2.3. By Application
    • 9.2.4. By Disease Indication
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Nanomedicine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Nanomolecule Type
        • 9.3.1.2.2. By Nanoparticles Type
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By Disease Indication
    • 9.3.2. UAE Nanomedicine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Nanomolecule Type
        • 9.3.2.2.2. By Nanoparticles Type
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By Disease Indication
    • 9.3.3. South Africa Nanomedicine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Nanomolecule Type
        • 9.3.3.2.2. By Nanoparticles Type
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By Disease Indication

10. South America Nanomedicine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Nanomolecule Type
    • 10.2.2. By Nanoparticles Type
    • 10.2.3. By Application
    • 10.2.4. By Disease Indication
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Nanomedicine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Nanomolecule Type
        • 10.3.1.2.2. By Nanoparticles Type
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By Disease Indication
    • 10.3.2. Colombia Nanomedicine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Nanomolecule Type
        • 10.3.2.2.2. By Nanoparticles Type
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By Disease Indication
    • 10.3.3. Argentina Nanomedicine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Nanomolecule Type
        • 10.3.3.2.2. By Nanoparticles Type
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By Disease Indication

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Nanomedicine Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Pfizer Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Johnson & Johnson Innovative Medicine
  • 15.3. Sanofi S.A.
  • 15.4. Amgen Inc.
  • 15.5. Moderna, Inc.
  • 15.6. Novo Nordisk A/S
  • 15.7. Genentech, Inc.
  • 15.8. Celgene Corporation
  • 15.9. Vifor Pharma Group
  • 15.10. Teva Pharmaceutical Industries Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer